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Abstract
Background: Glioblastoma are highly aggressive tumors with an average survival time of 12
months with currently available treatment. We have previously shown that specific embryonic
neural progenitor cells (NPC) have the potential to target glioma growth in the CNS of rats. The
neural progenitor cell treatment can cure approximately 40% of the animals with malignant gliomas
with no trace of a tumor burden 6 months after finishing the experiment. Furthermore, the NPCs
have been shown to respond to signals from the tumor environment resulting in specific migration
towards the tumor. Based on these results we wanted to investigate what factors could influence
the growth and progression of gliomas in our rodent model.
Methods:  Using microarrays we screened for candidate genes involved in the functional
mechanism of tumor inhibition by comparing glioma cell lines to neural progenitor cells with or
without anti-tumor activity. The expression of candidate genes was confirmed at RNA level by
quantitative RT-PCR and at the protein level by Western blots and immunocytochemistry.
Moreover, we have developed in vitro assays to mimic the antitumor effect seen in vivo.
Results:  We identified several targets involved in glioma growth and migration, specifically
CXCL1, CD81, TPT1, Gas6 and AXL proteins. We further showed that follistatin secretion from
the NPC has the potential to decrease tumor proliferation. In vitro co-cultures of NPC and tumor
cells resulted in the inhibition of tumor growth. The addition of antibodies against proteins selected
by gene and protein expression analysis either increased or decreased the proliferation rate of the
glioma cell lines in vitro.
Conclusion: These results suggest that these identified factors might be useful starting points for
performing future experiments directed towards a potential therapy against malignant gliomas.
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Background
Current treatment for GBM has proven ineffective mainly
due to the disseminating nature of the tumor in addition to
the resistance to irradiation and chemotherapy. Novel
approaches have tried to utilize the migratory potential of
neural progenitor cells (NPC) and their ability to function-
ally integrate into host tissues to target this invasive tumor
[1-6]. In previous studies we have shown that specific embry-
onic rat neural progenitor cells have the ability to target
malignant gliomas in the rat striatum [7]. These cells can
inhibit the growth of a solid tumor in the animals, prevent-
ing proliferation as well as invasion. The embryonic neural
progenitor cells are able to cure up to 40% of the animals in
co-inoculation experiments, with no trace of a tumor burden
6 months after finishing the experiment. This significant
antitumor effect is quite remarkable in light of the poor prog-
nosis displayed by glioma patients undergoing current treat-
ment regimens. We have further shown that these NPC upon
transplantation at a distance from a three day pre-established
primary tumor can migrate to the tumor and elicit an antitu-
mor effect [8]. This antitumor effect is demonstrated by a sig-
nificant reduction in tumor volume that is evident at early
time points and can be directly translated into survival stud-
ies of three day pre-established tumors, as shown by pro-
longed survival times for treated animals [8]. The objective of
this study was to find candidate genes involved in influenc-
ing tumor growth based on the strong antitumor effect
shown by the NPC. We hereby wanted to identify potential
targets or factors, which could prove effective in treating
malignant gliomas without the use of cell based therapy.
This was done by comparing gene and protein levels of NPCs
with antitumor effects vs. NPCs without antitumor effects as
well as comparing gene and protein levels of sensitive versus
insensitive tumors. A functional cross-comparison revealed
interesting gene and protein candidates that are both
involved in tumor growth as well as in tumor growth sup-
pression. These candidates were analyzed in initial func-
tional assays.
Methods
Cell lines
The rat glioma cell lines, N25, N29 and N32 (syngeneic
with the Fisher 344 line) were established and maintained
as previously described [9,10] in RPMI (GIBCO) supple-
mented with 10% fetal bovine serum (FBS, Sigma). The
rat embryonic neural progenitor cell lines HiB5 from hip-
pocampus [11], ST14A from striatum [12] and RN33B
derived from medullary raphe [13] were conditionally
immortalized with the temperature sensitive SV40 large T
and propagated as previously described [7,8] at the per-
missive temperature of 33°C. For RNA and histological
preparations, the cells were cultured under the non-per-
missive temperature of 39°C in serum free medium for
three days before harvesting or staining.
Microarray design
cDNA/oligo microarray slides were obtained from the
Swegene DNA Microarray Resource Center at Lund Uni-
versity, Sweden http://swegene.onk.lu.se. RNA, cDNA
synthesis, labeling, quality control and hybridizations
were performed according to previous publications [14].
The labeled cDNA was hybridized to rat 18 k microarray
slides which represents 5720 genes and scanned in a
G2565AA Agilent DNA Microarray Scanner (Agilent Tech-
nologies, Palo Alto, CA, USA). Spot analysis was per-
formed using GenePix 4.0 software (GenePix, Foster City,
CA, USA) and the subsequent data matrix was uploaded
to the BioArray Software Environment (BASE) [15]. Nor-
malizations, correction for bad quality spots, filter setups,
hierarchical clustering, and analysis was done in BASE
according to previous publication [16]. Results were ana-
lyzed with the software package BASE 1.2.17 (available at
http://base.onk.lu.se).
To analyze the genomic data, the following analysis was
performed: (I) cluster analysis of overall expression pro-
files in order to find relations between cell lines; (II) sta-
tistical analysis and (III) literature research and use of
gene ontology databases to distinguish between relevant
and non-relevant genes. Hierarchical clustering was per-
formed on 4,582 reporters remaining after data pre-
processing and filtering using a bottom-up approach with
center of mass linkage and Pearson correlation distance.
Statistical analysis required filtering of the dataset accord-
ing to the classification of the signals measured in 'absent'
(A) or 'present' (P). For statistical reasons, genes that were
not present in the entire microarray analyses were
excluded from the related comparisons [17]. Each cell line
was analyzed on a separate microarray and results were
compared afterwards.
The standard deviation in percent was calculated for the
different groups and only genes below a percent standard
deviation of 0.2 were taken into account. The minimum
fold change value was set to 2. Resulting genes were clas-
sified according to their functions against the background
of gene-ontology databases and the underlying literature
and experimental background. Statistical analysis was per-
formed using the software SAM (available at http://www-
stat.stanford.edu/~tibs/SAM/), which allows the detection
of falsely positive genes (family-wise error rate) by averag-
ing the amount of genes classified as significant over cho-
sen permutations of data between the groups. The false
discovery rate was set to false discovery rate £  1·10-4. After
statistical analysis, genes were selected according to the
highest fold change differences and their probable
involvement in cell proliferation.BMC Cancer 2009, 9:206 http://www.biomedcentral.com/1471-2407/9/206
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Real-time quantitative RT-PCR
Real-time quantitative RT-PCR was carried out on cDNA
from the glioma cell lines and the neural progenitor cell
lines using SYBR Green dye supermix for the ABI system
(Invitrogen, Carlsbad, Ca). Briefly, total RNA was pre-
pared from 80% confluent T75 culture flasks, by using
TRIzol (Invitrogen, Carlsbad, Ca) according to manufac-
turers protocol. In case of the progenitor cells, the cells
were grown in serum-free conditions and at the permis-
sive temperature of 37°C for 3 days. To remove remaining
genomic DNA, the samples were purified again and
DNase I treated by using RNeasy (Qiagen, Valencia, CA,
USA). cDNA preparations were conducted, using 1.5 mg of
RNA, according to manufacturers protocol (Superscript III
reverse transcriptase; Invitrogen) with the addition of
RNaseI (Promega). SYBR green PCR was done using a
7900HT Fast Real-Time System (Applied Biosystems, Fos-
ter City, CA). The PCR reactions were setup in 20 ml vol-
umes using a 2× SYBR Green PCR master mix (Invitrogen,
Carsbad, CA), 900 mM of each primer. In addition nega-
tive internal controls were used (no reverse transcriptase)
and GAPDH was used as a reference gene. The following
amplification program was used: 50°C for 2 minutes,
95°C for 10 minutes, 40 cycles of 95°C for 15 seconds,
60°C for 1 minute and 74°C 30 seconds and finally an
additional 15 seconds of 95°C. After cycling, relative
quantification of the specific mRNA expressions in the dif-
ferent cells was calculated and compared. Relative DNA
levels were quantified using the comparative Ct-method
according to User Bulletin #2, supplied by Applied Biosys-
tems http://www.appliedbiosystems.com. The following
primers where used (forward and reverse): Gas 6: 5'CTC-
CTACTCCTGCCTCT'3, 5'GCTGCCTGGGGAGTTGA'3,
CD81: 5' CATCCAGGAGTCCCAGT'3, 5'CAGCGTATT-
GGAGCCACA'3, AXL: 5'CTCTGGCTTCAAGATGCTGT'3,
5'GTGGTGACTCCCTTGGCA'3, Kai1: 5'CTGTGAGAA-
GACGAAGGA'3, 5'TGGAGAAGGCTCAGGCGTG'3,
GAPDH: 5'CTCCCTCAAGATTGTCAGCA'3, 5'GAGT-
GGCAGTGATGGCAT'3, FST: 5'GTGAAC-
GACAATACTCTCT'3, 5'GGTTTGTTCTTCTTGTTCA'3,
Arfd1: 5'CTGCCTCCACTGTGAAAAGA'3, 5'CTTCTG-
TAAACTGCTGCT'3, TPT1: 5'CTTGAAGAACA-
GAAACCA'3, 5'TAGTCCAGTAGAGCAACC'3, Camk2d:
5'CCTCTACATCTTGCTGGT'3, 5'CTGTGTCCCATTCT-
GGTGA'3, CXCL1: 5'CTTCAAGAACATCCAGAGT'3,
5'CATTCTTGAGTGTGGCT'3, Eef1a: 5'CAGGCACATCT-
CAGGCT'3, 5'AGTGGCTTACACTTTGG'3.
Intracerebral stereotactic injections
N32 tumor cells (2 × 103 cells) and embryonic neural pro-
genitor cells ST14A (2.5 × 105 cells) were stereotactically
co-injected into Fisher rats (as described in [7]) using 5
animals/group. Animals were anesthetized with Isoflour-
ane (2% in NO and O2) and given Marcain Adrenalin (2.5
mg/ml+5 mg/ml, Astra Zeneca, Sweden) subcutaneously
into the skin covering the scull, before stereotactically
(Kopf Instruments, Tujunga, CA) given intracerebral inoc-
ulations into the right striatum (anterior, 1.7, medi-
olateral -2.5, ventral -4.5 measured from the bregma and
the dural surface). Injection of cells was made using a
Hamilton syringe in a maximum of 3 ml RPMI medium
supplemented with 1% Fisher rat serum. All animals were
treated according to the Swedish guidelines for humane
treatment of laboratory animals and the experiments were
approved by the Lund/Malmö animal ethical committee.
The animals were monitored daily and examined for any
signs of distress, ataxia, abnormal movements, appetite
loss or decrease in activity and sacrificed upon showing
motor function deficits according to the Swedish guide-
lines for humane treatment. Kaplan Meier Survival curves
were analyzed using the chi-square test with a p-value of p
= 0.0035 between the groups.
Immunocytochemistry and Immunohistochemistry
Fluorescent immunohistochemical staining was per-
formed by rinsing cell slides in KPBS, blocking in appro-
priate serum 1 h followed by primary antibody
incubation; polyclonal rb anti-TPT1 (10824-1-AP Protein
Tech Group, Chicago, IL), blocking goat anti-Follistatin
(AF669 R&D systems, Germany), biotin conjugated ham-
ster anti-CD81 monoclonal (TAPA1, 559518 BD
Pharmingen), rb anti-AXL (4977 Cell Signaling Tec.) over-
night in 5% NDS, 0.25% Triton X-100. This was followed
by rinsing and incubation for 2 h with secondary antibod-
ies donkey anti-goat Cy2, streptavidin Cy2, donkey or rab-
bit Cy2 (all 1:400, Jackson, West Grove, PA). The sections
were mounted on a cover slip using PVA-DABCO. The
usage of patient glioblastoma multiforme tumor samples
has been accepted by the Local Ethical Board of the Uni-
versity of Lund. Tumor pieces from surgical resection were
transferred to IMDM cell culturing medium (GIBCO-Inv-
itrogen, Carlsbad, CA, USA) before being snap-frozen in
Isopentane at a temperature of -50°C. Tissues were then
kept in -80°C until sectioning on a cryostat. Seven mm
thick sections were cut and mounted directly onto glass
slides. For immunohistochemical staining, sections were
fixed in room-tempered acetone for 10 minutes and
rinsed in PBS (GIBCO-Invitrogen, Carlsbad, CA, USA). To
permeabilize the cells, PBS containing 0.1% saponin
(Riedel-de Haen, Seelze, Germany) was used as washing
buffer and diluent in all steps. Sections were blocked with
5% goat serum (Jackson ImmunoResearch Laboratories
Inc. West Grove, P.A, USA) for 20 minutes and incubated
with the primary antibody mouse anti-human follistatin
(R&D Systems, Minneapolis, MN, USA) for 60 minutes in
room temperature (RT). Sections were then washed and
incubated for 30 minutes in RT with the secondary anti-
body, goat-anti mouse Alexa 488 (Molecular Probes,
Eugene, Oregon, USA). The slides were mounted wet
using Pro-Long Gold anti-fading reagent, (MolecularBMC Cancer 2009, 9:206 http://www.biomedcentral.com/1471-2407/9/206
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Probes), with nuclear staining (DAPI). As negative con-
trol, the primary antibody was omitted. Stained cells were
analyzed by the use of a light microscope (BX-60, Olym-
pus America Inc., Melville NY, USA), equipped with a
mercury lamp and filters for fluorescence (U-MWG, U-
MWB, U-MWU, Olympus). Images were taken in 20×
magnification using an Olympus Color View digital cam-
era and captured using the analySIS® Image analysis soft-
ware (Olympus).
Western Blot
Western blots were performed according to protocols
from Bio-Rad Laboratories, CA. The protein analysis was
performed using the primary antibodies; polyclonal rb
anti-CXCL1 (1:1000 ab17561 Abcam, Cambridge, UK),
goat anti-Gas6 (1:1000, AF986 R&D systems, Germany).
Subsequent secondary antibody staining was done using:
goat anti-rabbit IgG-HRP, donkey anti-goat IgG-HRP (sc-
2004, sc-2020, Santa Cruz Biotechnology) 1:5000.
In vitro proliferation assay
Tumor cells (N32: 600 cells/w, N25/N29: 1000 cells/w)
were seeded into 96 well plates either alone or together
with irradiated progenitor cells (10 000 rad; 37 Cs source)
(HiB5/ST14A/RN33B: 10 000–20 000 cells/w). After
allowing the cells to attach, antibodies against FST/CD81/
CXCL1/AXL/GAS6/TPT1 (as described above) were added
at concentrations suggested by the manufacturer (0.1–1
mg/ml). Recombinant follistatin protein was added at a
concentration of 5–10 nM to the tumor cells. After cultur-
ing the cells at 37°C for three days they were pulsed with
0.5  mCi  3H-thymidine (Amersham, Buckinghamshire,
UK) for 6 h and the cells were subsequently harvested in a
Tomtec cell harvester and 3H-thymidine incorporation
was measured using a Wallac 1450 Microbeta Liquid Scin-
tillation Counter (Turku Finland). The assays were
repeated three times with a minimum of quadruplicates
per assay. Statistical analysis was measured using the
GraphPad program (GraphPad Prism version 4.00 for
windows, San Diego, CA). Differences between means of
two groups were tested using a t-test/as well as Mann whit-
ney test, with significance P < 0.05. These data are
expressed as fold changes based on the effect of NPC on
tumor growth alone.
Results
In our previous study, the two embryonic rat progenitor
cell lines HiB5 and ST14A showed a strong antitumor
effect on syngeneic malignant glioma models in vivo [7,8].
Previous successful treatment regimens were based on
using tumor verses NPC cell ratios ranging from 1:5–
1:100. To gain insight into the efficacy in treating tumors
with NPC, new experiments were designed to maximize
the antitumor effect using a 1:125 ratio. This was done in
order to identify factors contributing to the antitumor
effect. Injections of the NPC cell line ST14A into the stria-
tum of Fisher rats show antitumorigenic properties
towards the malignant glioma N32 if co-inoculated into
the striatum. All animals receiving N32 tumor had to be
sacrificed by day 22 post injection due to tumor related
symptoms whereas animals co-inoculated with ST14A
showed a prolonged lifespan and a cure of up to 40% of
the animals (Figure 1). In cured animals there was no
trace of tumor growth after six months as investigated by
histological examination (data not shown).
Classification of differently expressed genes in progenitor 
cells and glioma cells
Microarray analysis was carried out to screen the tumor
cells and NPC with the goal to find putative genes
involved in glioma growth and invasion. Thereby, we
hoped to identify factors that could be used for future
therapy, circumventing the use of elaborate NPC trans-
plants. Comparative analysis was carried out on the
malignant gliomas N32 and N29, which have been shown
to be sensitive to treatment with NPC, versus the glioma
N25 that showed no response to treatment. The initial
array clustering analysis revealed the level of genetic
resemblance between the cell lines (Figure 2). The den-
drogram, which is based on the complete array results
after pre-processing and filtering, shows that the two
NPCs (HiB5/St14A) which display antitumor properties
cluster together. The cell line RN33B, which has no anti-
tumor properties, show a greater resemblance with the
tumors (the whole cluster analysis is shown in additional
file 1). The gene expression profile of the gliomas were
cross compared with the array data from the embryonic
neural progenitor cells HiB5/ST14 and RN33B, where the
latter has no antitumor properties. Additional cross com-
parisons within tumor- and NPC-groups were also made.
The top regulated genes for each comparison are shown in
Table 1. Genes were sorted into different groups of interest
such as growth factors, metabolism, cell cycle, cell death
and then screened in proteomic databases. We chose to
continue with 10 genes for quantitative PCR analysis and
6 of those were also confirmed by protein expression anal-
ysis using either western blots or immunocytochemistry
(Table 2). AXL was not present on the array chip, but is the
receptor for Gas6 and was therefore added to the protein
analysis. All gene products that were selected for charac-
terization by protein expression levels were either secreted
or membrane-bound proteins. Some have been shown
previously to be of importance for tumor growth, inva-
sion, metastasis and/or chemotaxis, such as Gas6/AXL
and CXCL1 [26,27].
Validation of candidate genes
To confirm the gene expression of the selected genes on
RNA and protein levels we performed RT-PCR, immuno-
cytochemistry and western blot analysis (Table 2).BMC Cancer 2009, 9:206 http://www.biomedcentral.com/1471-2407/9/206
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Genes highly expressed in the NPC displaying antitumor
effects (HiB5/ST14A), according to RNA and protein lev-
els (Figure 3, table 2), were follistatin, Growth arrest spe-
cific 6 (Gas6) and ADP-ribosylation factor domain 1
(Arfd1). Expressed genes found in both the tumor group
and the NPC with antitumor effect were Camk2, CD81,
Kai1, TPT1 and AXL. These genes were not expressed at all
or less expressed by the control embryonic cell line
RN33B which does not display any antitumor effects.
Eef1a was differentially expressed in the different types of
tumors and NPC.
Histology of protein expression revealed high follistatin
expression by HiB5 and ST14A with very weak expression
in N25 and no expression in the other cell lines, correlat-
ing with RT-PCR and microarray data (Figure 3a–f). Since
follistatin is an activin inhibitor [18], we screened the
tumors for activin expression using RT-PCR. All three gli-
omas expressed activin on the RNA level (Figure 3S). Gas6
is a secreted protein shown to be involved in tumor cell
proliferation and invasion. Expression was found in HiB5
and ST14A, with lower levels in RN33B and no expression
in the tumors (Figure 3S). The Gas6 receptor AXL and the
cell surface molecule CD81 were abundantly expressed on
the tumors and on HiB5/ST14A (Figure 3, g–r).
The chemokine/growth factor CXCL1 protein was exclu-
sively expressed by the sensitive tumors N32 and N29
(Figure 3S). CXCL1 has previously been implicated in
promoting angiogenesis and oncogenesis in various can-
cer types, including gliomas [19-21]. The RNA and protein
expression levels correlate for the majority of the selected
targets with the following exceptions: TPT1 (Tumor pro-
tein, translationally-controlled 1) which is a translation-
ally controlled protein, CXCL1 and partially for Camk2.
In vitro functional assays demonstrating effects on tumor 
proliferation
To get a preliminary evaluation of the selected genes in the
interaction of glioma cells with NPCs, we performed a
functional in vitro assay measuring cell proliferation. In
vivo there is a slower progression in tumor growth with
time in the presence of NPC [7,8]. This is mimicked by the
inhibition of tumor proliferation if co-cultured with NPC
in vitro [7]. In co-cultures of tumor cells together with irra-
diated non proliferating NPC we have in previous studies
shown that HiB5 and ST14A can inhibit the tumor prolif-
eration of N32 and N29 in vitro, but not of N25, thereby
giving us a potential model system for measuring the anti-
tumor effect seen in vivo. RN33B has no effect on tumor
growth in vivo or in vitro [7]. We here performed func-
tional assays using antibodies against the proteins follista-
tin, Gas6, AXL, CXCL1, CD81 and TPT1, added to either
single tumor or progenitor cell cultures or co-cultures of
tumor and progenitor cells at day 0.
Co-cultures of either HiB5 or ST14A with N32/N29 show
an inhibition in tumor proliferation as compared to single
cultures of tumor cells. Counts per minute (CPM) for single
cultures with N32 ranged between 5796–13069 ± 180–200
cpm and for N29 between 1115–7133 ± 73–235 cpm
depending on the number of cells used. The relative inhibi-
tion by HiB5 or ST14A decreased the proliferation of the
tumor N29 by 77–91% and 76–94% respectively. For the
glioma N32, the proliferation decreased with 89–96% and
57–88% in the case of treatment with HiB5 or ST14A
respectively. N25 was insensitive to the antitumor effect
elicited by the progenitor cells (data not shown). This level
of inhibition on tumor cell division by the NPC was set as
the baseline level (1), without the addition of antibodies.
Co-cultures were subsequently treated with antibodies at
day0 and measurements were made at day 3. Addition of
antibodies at day 0 either increased the inhibition of NPC
on glioma proliferation (values below 1) or counteracted
the inhibition of cell proliferation (values above 1). Some
of these antibodies are not confirmed as blocking antibod-
ies and hence there is a possibility that they do not target
the functionality of the protein in an optimal way. On the
other hand, controls using isotype IgG did not show any
effect (data not shown), suggesting that the specific anti-
bodies interacted with target protein functionality.
Follistatin protein was shown to be expressed exclusively
by HiB5/ST14A (Figure 3f–g). The addition of a blocking
Prolonged animal survival is seen after co-inoculation of gli- oma with NPC Figure 1
Prolonged animal survival is seen after co-inoculation 
of glioma with NPC. Co-inoculation of NPC together with 
glioma cells into the striatum of experimental fisher rats 
result in reduced tumor growth. The glioma N32 (2 × 103 
cells) was stereotactically co-injected with the NPC, ST14A 
(2.5 × 104) into the striatum of fisher rats (n = 5/group). 
Antitumor properties for the other NPC lines are shown in 
our previous publications (Staflin et al. 2004, 2007). The per-
cent survival was followed over time and statistical analysis of 
the Kaplan Meier curve was done using a chi square test **p 
= 0.0035.BMC Cancer 2009, 9:206 http://www.biomedcentral.com/1471-2407/9/206
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antibody to follistatin in co-cultures increased the tumor
proliferation, indicating that follistatin is involved in the
inhibition of tumor proliferation. The antibody signifi-
cantly counteracted the HiB5 cells inhibitory effect on gli-
oma proliferation and to a lesser extent influenced the
effect of ST14A on tumor growth (Figure 4). Addition of
blocking antibody to single cultures of tumor (N32/N29/
N25) had no influence on tumor growth (data not
shown). Addition of follistatin antibody to cultures of
NPC weakly decreased their proliferation, indicating that
follistatin might have a paracrine/autocrine regulatory
function in cell division for the NPC themselves (data not
shown). Further, the addition of recombinant follistatin
protein to cultures of N29 showed an inhibition of prolif-
eration by 33% compared to the control after three days.
Control cultures (N29) had a proliferation of; CPM 2699
± 95 and the addition of follistatin resulted in a decreased
CPM to 1818 ± 140. Addition of antibodies against the
other five selected genes to co-cultures either had no effect
or resulted in a reduction of tumor proliferation (Figure
5A–B). This suggests that some of these proteins may be
involved in promoting tumor growth. This can be exem-
plified by the Gas6/AXL system where the addition of
antibodies against the protein Gas 6 potentiated the inhi-
bition elicited by the NPC on the N29 tumor and to a
lesser extent on N32 (Figure 5A–B). This was further
strengthened by the fact that addition of antibodies
against the Gas6 receptor AXL also increased the inhibi-
tion of tumor proliferation on N29 and N32 using HiB5
(Figure 5A–B).
Addition of antibodies against CXCL1, CD81, and TPT1
had various effects either inhibiting the tumor prolifera-
tion or showing no significant changes upon the tumors
(Figure 5).
Follistatin expression by human gliomas
To validate the expression of follistatin in human gliomas
we stained four human glioblastoma multiforme (GBM)
grade IV tumors with an antibody recognizing follistatin.
Tumor stroma as well as some infiltrating microglia/mac-
rophage-like cells were found to be follistatin positive. In
addition, there were distinct sub-populations of tumor
cells within the tumor bulk, which were follistatin posi-
tive (Figure 6A–B). Two out of four GBMs were low to
moderately positive (A) and two showed a higher degree
of positivity (B). Two representative tumors are shown in
figure 6. This suggests that follistatin has a role in glioma
growth and might be of interest as a potential marker for
glioma grade as well as for tumor progression.
Discussion
The majority of the glioblastoma cases are primary gliob-
lastomas, hence developed de novo displaying aberra-
tions in the EGFR expression, p16INK4a, and PTEN
mutations [22,23]. Secondary glioblastomas arise from
the progression of lower grade tumors and often display
TP53 mutations. The characterisation of relevant protein
markers and targets for glioma are identified with the
ATLAS project and confirms the relevance of genes such as
CD81, and InhibinB [24]. The underlying genetical aber-
rations in our glioma models are currently unknown but
most gliomas have one or more dysfunction in signalling
pathways regulating growth factor signalling (EGF/
PDGF), p53/Rb tumor suppressors and or PI3K/PTEN
pathways [23,24]. The TGFb-family also plays a role in the
Table 1: The top regulated genes from the array for each 
comparison.
Gene Fold change N29 and N32 vs N25
Cryac 33.06
Prss1 8.41
Prrx1 6.08
Lgals3 5.04
Faf1 4.45
Kcnd2 0.34
Camk2n2 0.32
Tgfb1i4 0.31
Igfbp5 0.24
Fst 0.14
Gene Fold change ST14a and Hib5 vs Rn33b
Fst 155.25
Cryac 62.76
Smgb 41.11
Prss1 35.74
Gas6 11.90
Hfb2 0.26
Dbi 0.19
Map17 0.15
Pitx2 0.12
Col18a1 0.06
Gene Fold change glioma/NPC
Col3a1 7.13
Pga5 2.75
Nme1 1.94
Rasa1 1.84
Hfb2 1.81
Gas6 0.12
Mch 0.10
Mcl1 0.09
Smgb 0.07
Fst 0.04
Microarray comparisons. Shown are the fold changes of the five most 
up- or downregulated genes for the following comparisons: N29 and 
N32 vs. N25, ST14A and Hib5 vs. RN33b, Glioma vs. NPCs. Statistical 
analysis was performed using the software SAM, which allows the 
detection of falsely positive genes (family-wise error rate) by 
averaging the amount of genes classified as significant over chosen 
permutations of data between the groups. The false discovery rate 
was set to false discovery rate £  1 10-4.BMC Cancer 2009, 9:206 http://www.biomedcentral.com/1471-2407/9/206
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progression of gliomas and consists of activins, inhibins
and bone morphogenic proteins (BMP). This family regu-
lates known oncogenes such as c-myc as well as p15INK
and P21 CIP and have also been found to be responsible
for the dysregulation of growth factor pathways in glioma
[25]. Our data implies that the TGFb family member fol-
listatin is of importance for regulating glioma growth. The
relevance and importance of the selected genes presented
in our work is shown by the fact that the majority are
found to be over expressed in human glioblastoma multi-
forme. These include CXCL1, AXL and Gas6 which pro-
vide negative prognostic markers for the disease [26,27].
The aim of this study was to find candidate genes involved
in affecting tumor proliferation and progression based on
previous findings that specific progenitor cells are able to
affect glioma growth in the CNS [7,8,28-30]. By character-
izing the two embryonic NPCs for their properties in tar-
geting tumors we could potentially isolate and supply a
tool for future treatments of highly malignant gliomas
without using cell based therapy. Further, the characteri-
zation of the tumors together with the NPC would reveal
genes and proteins important for tumor growth and inva-
sion that might be transferred to human tumors. The ini-
tial microarray analysis revealed that in fact the two NPC
with antitumor properties cluster together. This shows a
certain similarity on the gene level between these lines
translating into their ability to affect tumor growth. The
genes that were selected from the microarray analysis,
based on known localization and function, were con-
firmed on RNA and protein levels. Highly expressed genes
in HiB5 and ST14A such as follistatin, a TGFb-family
antagonist, and Gas6 are known to be involved in cell pro-
liferation and migration. In addition they have the ability
to influence the growth of tumor cells. NPC have a great
self renewing and proliferative potential [31] and might
rely in part on similar signaling pathways as tumor cells
originating from the brain, such as gliomas. This would
explain the found similarity between the cell populations
as well as their ability to influence each other as shown in
previous work [7,8]. One example is the importance of
the TGFb family and SMAD signaling in regulating stem
cell multipotency, self renewal and differentiation as well
as their role in regulating tumorigenesis [32].
In vivo we observe a decreased tumor growth rate in the
presence of NPC. In vitro models are inefficient in mimick-
ing the complexity of the in vivo environment, but can
serve the purpose of illustrating important mechanisms
that might be a part of the in vivo scenario, such as inhibi-
tion of tumor proliferation. The in vitro screening assays
performed in this study, using specific antibodies against
protein candidates, validated the tumor-inhibiting or pro-
moting effect of those proteins and gave valuable hints
that underline the importance of the mechanisms behind
those effects. Blocking follistatin secretion from HiB5/
ST14A in tumor co-cultures resulted in an increased pro-
liferation rate of the tumor cells. This, together with the
finding that the addition of recombinant follistatin on
tumor cells inhibited N29 proliferation by 30%, might
suggest a potential role for follistatin in regulating glioma
growth. Follistatins are extracellular proteins, which bind
TGFb-family members such as BMPs and activins (espe-
cially activin A) with high affinity, blocking their receptor
interaction [18]. The TGFb-family members are potent
regulators of cell growth, cell survival and differentiation
in many different cell types [25,33]. In malignant disease,
family members such as TGFb, BMP and activin can act as
tumor suppressors or as promoters of tumor growth [32-
36]. The activin and follistatin balance has been shown to
be dysregulated in numerous solid tumors, such as pros-
tate cancer and hepatocarcinogenesis [37,38] and the
development of resistance to TGFb growth inhibition is a
key event in tumor progression [37,25]. We show that rat
gliomas express activin, however there are other TGFb-
family members that might be relevant to look at as
potential targets for follistatin regulation, such as the
BMPs, which have similar growth and survival regulatory
functions. Most cell types and some tumors respond with
growth arrest to TGFb-family members such as activin, by
many different mechanisms, including upregulation of
cell cycle inhibitors. This is usually mediated via SMAD
dependent signaling pathways [39]. In other instances,
NPC with antitumor properties show a high genetic sem- blance Figure 2
NPC with antitumor properties show a high genetic 
semblance. Dendrogram of the genetical semblance 
between the gliomas N25, N32 and N29 as well as their rela-
tionship with the NPC HiB5, ST14A and RN33B. The 
arrangement is based on the initial array after pre-processing 
and filtering, before further steps for selecting genes were 
performed. The two NPC with antitumor effect cluster 
together and RN33B lacking antitumor effect clusters 
together with the gliomas. Hierarchical clustering and analy-
sis was done with the software package BASE 1.2.17 (availa-
ble at http://base.onk.lu.se). For the whole cluster analysis 
see Additional file 1.BMC Cancer 2009, 9:206 http://www.biomedcentral.com/1471-2407/9/206
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the tumor cells have become non-responsive to cell cycle
regulation by TGFb-family members and instead produce
TGFb/activin/BMP that have a beneficial role for the
tumor development e.g. modulating tumor matrix, adhe-
sion molecules and suppress the immune system [18,40-
45]. This has been shown to occur in part via SMAD inde-
pendent signaling pathways [18,39]. The production of
follistatin by NPCs resulting in tumor-growth inhibition
could be mediated by many different mechanisms in vivo
e.g. inhibition of immuno-suppression, dysregulation of
matrix production or direct anti-proliferative effects on
the tumor. The increase in growth after the addition of fol-
listatin antibodies in vitro, or the direct inhibitory effects
of recombinant follistatin on glioma proliferation might
hence influence important cell maintenance signals or
directly impact cell proliferation e.g. by modulating the
matrix. We evaluated the expression of follistatin in sev-
eral grade IV human gliomas and found a subpopulation
within these tumors which express follistatin. This might
suggest that the tumor acquires similar mechanisms to
increase the resistance to growth inhibitory effects, medi-
ated by follistatins, as seen with other TGFb-family mem-
bers such as Activin and TFGb. With higher grade, gliomas
may become more resistant to growth inhibitory signals
from TGFb-family members since it confers a survival
advantage for the tumor. In addition, becoming resistant
to these growth inhibitory signals is vital to escape the
effects of infiltrating immune cells secreting inhibitory
Table 2: Expression profiles of selected genes and proteins from microarray analysis, RT-PCR, immunocytochemistry and western blot 
analysis.
GENE CELL N25 N32 N29 RN33B ST14A HIB5 ANALYSIS
Follistatin + - +/- - +++ +++ Microarray
+ --- + + + + + RT-PCR
+ +/- - - +++ +++ Protein exp
GAS6 (growth arrest specific protein 6) +/- +/- +/- +/- +++ +++ Microarray
+/- +/- +/- - +++ ++ RT-PCR
---+ / - + + + + Protein exp
TAPA1/CD81 + missing ++ + +++ +++ Microarray
++ + + ++ / -+ + + + + RT-PCR
++ +++ +++ - ++ +++ Protein exp
AXL missing missing missing missing missing missing Microarray
++ + ++ + +++ ++ RT-PCR
+++ ++ +++ - ++ +++ Protein exp
GRO1/CXCL1 (chemokine (C-X-C motif) ligand 1) +++ ++ ++ ++ + + Microarray
++ +++ + - ++ ++ RT-PCR
-+ + + + + - - -Protein exp
TPT1 (tumor protein, translationally controlled 1) ++ + ++ +/- +++ +++ Microarray
+++ ++ + +/- ++ + RT-PCR
T R I M 2 3 / A r f d 1  ( t r i p a r t i t e  m o t i f - c o n t a i n i n g  2 3 ) ++++ + + + + + + Microarray
++++ ++ + + + + RT-PCR
CD82/Kai1 ++ ++ +++ + +++ +++ Microarray
+++ ++ ++ + +++ +++ RT-PCR
Camk2 (Ca/calmodulin dependent protein kinase typeII) ++ + + + +++ ++ Microarray
++ +++ + + ++ ++ RT-PCR
Eef1a (Elongation factor 1 alpha) ++ + + + +++ +++ Microarray
+++ + + + ++ ++ RT-PCR
The order of the scores in the table is 1) microarray, 2) RT-PCR, 3) protein analysis. The selected and compared genes were: Growth arrest 
specific 6 (gas6), follistatin (fst), AXL receptor tyrosine kinase (missing on the array), translationally-controlled 1 (TPT1), Kai (CD82), CD81 (Tapa-
1), ADP-ribosylation factor domain protein 1 (Arfd1), Calcium/calmodulin-dependent protein kinase II (Camk2), growth regulated protein 
precursor CXCL1 and Eukaryotic translation elongation factor 1 alpha 1 (Eefa1). The levels of expression are compared within each method of 
measurement used and expressed within each group as +++ for the strongest expression measured. ++ was set for values ranging from 45–70% of 
the highest score (+) for 15–44% of the highest score, (+/-) for 1–14% of the highest score and (-) for no expression detected.BMC Cancer 2009, 9:206 http://www.biomedcentral.com/1471-2407/9/206
Page 9 of 14
(page number not for citation purposes)
BMPs and TGFb. In support of this notion is the fact that
the follistatin homolog follistatin like protein 1 has been
shown to be a negative prognostic factor and is abun-
dantly expressed in high grade gliomas [46]. It would be
of interest to investigate if the expression of follistatin
increases with glioma grade in accordance with follistatin
like protein [46]. Our rat glioma cell lines cannot be
graded according to the WHO but have similarities to
grade III-IV gliomas. Human gliomas are of much higher
cellular diversity than the rat glioma cell lines used in this
study. Therefore, only a fraction of human tumor cells
within a glioma may respond in the same way as in our
experimental model. This also demonstrates that the het-
erogeneity of the cells within a tumor make them poten-
tially respond different to treatment regimens and might
explain why some of our experimental tumors do not
respond to NPC treatment. The glioma N25 is one such
example, where the tumor might have gained a resistance
to TGFb family related growth inhibitory effects. This cell
line was shown to be weakly positive for follistatin in cul-
ture in contrast to the gliomas which respond with growth
arrest to the NPC.
Follistatin is a good candidate for the tumor inhibition
observed by the embryonic progenitor cell lines HiB5 and
ST14A. It will be of great importance to test the feasibility
of the approach in vivo, to use tools for blocking the
actions of follistatin in animals with gliomas and in ani-
mals receiving NPC treatments (using e.g. siRNA or anti-
bodies). Indeed, our initial investigations of follistatin
expression by the NPCs after transplantation to the rat
brain suggest that they sustain the follistatin expression in
vivo (K. Staflin, unpublished observation). These findings
provide a basis for further investigation into the role of
follistatin in cancer development in vivo.
In addition, several other proteins were identified which
might be of importance for regulating the ability of the gli-
omas to grow and invade. The Gas6-AXL pathway is
involved in tumor stimulating actions such as stimulating
growth and invasion as well as in anti tumor actions,
increasing leukocyte transmigration from vessels impor-
tant in tumor targeting [47-51]. The Gas6/AXL pathway
has also been shown to protect epithelial/endothelial cells
from apoptosis and has been suggested to play an impor-
tant role in tumor vascularization [27]. This implies that
targeting the Gas6/AXL pathway in gliomas might not
only have direct effects on tumor proliferation signals but
could have secondary effects by decreasing the vasculari-
Validation of protein expression Figure 3
Validation of protein expression. Immunocytochemical analysis of protein expression of (a-f) Follistatin, (g-l) CD81, (m-r) 
AXL, Scale bars indicate 50 mm. (s) total protein expression analysis of the proteins Gas6 and CXCL1 comparing gliomas (N25, 
N29, N32) and NPC (HiB5, ST14A, RN33B). As well as RT-PCR analysis of activin expression in the tumors.BMC Cancer 2009, 9:206 http://www.biomedcentral.com/1471-2407/9/206
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Blocking antibody against the follistatin protein results in an increased tumor proliferation Figure 4
Blocking antibody against the follistatin protein results in an increased tumor proliferation. Co-cultures of tumor 
N29 (A) and N32 (B) together with irradiated NPC (HiB5/ST14A), were treated by adding an antibody targeting the follistatin 
protein. Cells were seeded together and allowed to attach before addition of the antibodies. The plates were pulsed with 3H-
thymidine after 3 days in culture and cell division was measured as the amount of incorporated 3H-thymidine. White bars show 
the proliferation of NPC + tumor control cultures and black bars show the proliferation after the addition of follistatin anti-
body. Mean ± stdev: Statistical analysis was made using t-test and Mann Whitney Wilcoxon rank sum test * P < 0.05.BMC Cancer 2009, 9:206 http://www.biomedcentral.com/1471-2407/9/206
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A decrease in tumor proliferation after the addition of antibodies against the genes Gas6, AXL, CXCL1, CD81 and TPT1 was  observed Figure 5
A decrease in tumor proliferation after the addition of antibodies against the genes Gas6, AXL, CXCL1, CD81 
and TPT1 was observed. Co-cultures of tumor N29 (A) and N32 (B) together with irradiated NPC (HiB5/ST14A), were 
treated by adding antibodies against Gas6, AXL, TPT1, CXCL1 and CD81. Cells were seeded together and allowed to attach 
before addition of the antibodies. The plates were pulsed with 3H-thymidine after 3 days in culture and cell division was meas-
ured as the amount of incorporated 3H-thymidine. The result is expressed as fold change, where 1 represents the inhibition by 
NPC alone on the tumor (dashed line). Values below 1 show a further decrease in tumor proliferation due to the addition of 
antibodies. White bars show HiB5 and black bars show ST14A cultures. Mean ± stdev: Statistical analysis was made using t-test 
and Mann Whitney Wilcoxon rank sum test * P < 0.05BMC Cancer 2009, 9:206 http://www.biomedcentral.com/1471-2407/9/206
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zation of the tumor and may present a good target for gli-
oma therapy.
Our results show an increased inhibition of tumor growth
by the NPC with the addition of either antibodies to these
proteins, which point towards an implication of the
importance for Gas6-AXL signaling in promoting tumor
growth in vitro in the syngeneic rat glioma models. These
results have relevance for the treatment of human GBM
since both these proteins have been shown to be overex-
pressed in human gliomas and act as negative prognostic
factors for the disease [27]. The N32 glioma was less
responsive to the blocking of Gas6 and AXL signaling.
This unresponsiveness might explain the difference in
invasion capability of the tumors, with N29 being
strongly invasive and N32 being less invasive [7]. Previous
studies show that CXCL1 mediates glial progenitor cell
proliferation during development of the brain but it has
also been shown to have a role in the promotion of ang-
iogenesis, oncogenesis in prostate cancer, in melanomas
and in increased tumorigenicity of gliomas [19-21]. When
antibodies specific for CXCL1, TPT1 or CD81 were added
to tumor co-cultures with NPC, the suppressive effect by
the NPC was significantly enhanced in several combina-
tions of NPC and tumor, although to a varying extent.
This clearly argues for a promoting effect of some of those
factors on tumor growth. For CXCL1 and TPT1, this tumor
proliferative effect is already known [21,26,52]. However,
we were able to show that this proliferative effect also
applies to the specific gliomas N32 and N29. The fact that
addition of an antibody enhances the suppressive effect of
HiB5 and ST14A on tumor growth gives hints that the
suppressive effect of these NPC is not due to their secre-
tion of TPT1, CD81 and CXCL1, Gas6/Axl but to other fac-
tors. Furthermore, identification of these proliferation
promoting factors would allow the genetic modification
of the NPC lines HiB5 and ST14A to optimize their effects
for future experiments. CD81 has not yet been clearly
identified as either tumor growth suppressor or enhancer.
We were able to show that CD81 has a proliferative effect
on tumor growth of N29 and N32. This is in line with
findings in Geisert et al. 2002 [53] and argues for future
experiments looking for options to suppress CD81 expres-
sion as a possible candidate for tumor treatment. Candi-
dates, displaying both positive and negative effects on
glioma proliferation were characterized. Specific candi-
dates like follistatin and the Gas6/AXL system, point
towards future experiments evaluating them in more
detail as targets for future therapy of gliomas.
Conclusion
Taken together, we have identified several putative factors
that influence rat glioma growth and were able to further
characterize the NPC cell line backgrounds from which
these factors were secreted in our experimental setup. The
factors identified might be useful starting points for per-
forming future experiments directed towards a possible
therapy against malignant gliomas.
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A subpopulation of grade IV human GBM display follistatin  expression Figure 6
A subpopulation of grade IV human GBM display fol-
listatin expression. Figure 6. Follistatin expression by sub-
sets of tumor cells within the glioblastoma multiforme (GBM) 
tumor cell bulk. Samples from GBM patients were freeze sec-
tioned and subsequently stained using a follistatin antibody 
against the human antigen. A) Central tumor sections of 
patient A. A few selectively follistatin positive cells are seen 
within the central portions of the tumor. B) Central section 
from patient B. Follistatin expression is seen in a subset of 
tumor cells within the central bulk of the tumor. The histo-
logical examination of patient A and B tumors displays a het-
erogeneity within the tumor bulk with both positive and 
negative tumor cells. As negative control, the primary anti-
body was omitted, C. Scale bars indicate 50 mm.BMC Cancer 2009, 9:206 http://www.biomedcentral.com/1471-2407/9/206
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